Emery S - Search Results

1

Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens.

Kelleher AD, Roggensack M, Emery S, Carr A, French MA, Cooper DA. Kelleher AD, et al. Among authors: emery s. Clin Exp Immunol. 1998 Jul;113(1):85-91. doi: 10.1046/j.1365-2249.1998.00633.x. Clin Exp Immunol. 1998. PMID: 9697988 Free PMC article. Clinical Trial.

2

CD8+ lymphocyte responses to antiretroviral therapy of HIV infection.

Carr A, Emery S, Kelleher A, Law M, Cooper DA. Carr A, et al. Among authors: emery s. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Dec 1;13(4):320-6. doi: 10.1097/00042560-199612010-00004. J Acquir Immune Defic Syndr Hum Retrovirol. 1996. PMID: 8948369 Clinical Trial.

3

Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group.

Carr A, Emery S, Lloyd A, Hoy J, Garsia R, French M, Stewart G, Fyfe G, Cooper DA. Carr A, et al. Among authors: emery s. J Infect Dis. 1998 Oct;178(4):992-9. doi: 10.1086/515653. J Infect Dis. 1998. PMID: 9806026 Clinical Trial.

4

Antiretroviral therapy of human immunodeficiency virus type-1 (HIV-1) infection.

Emery S, Cooper DA. Emery S, et al. Aust N Z J Med. 1995 Aug;25(4):344-9. doi: 10.1111/j.1445-5994.1995.tb01900.x. Aust N Z J Med. 1995. PMID: 8540876 Review. No abstract available.

5

Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection.

Kelleher AD, Emery S, Cunningham P, Duncombe C, Carr A, Golding H, Forde S, Hudson J, Roggensack M, Forrest BD, Cooper DA. Kelleher AD, et al. Among authors: emery s. AIDS Res Hum Retroviruses. 1997 Jan 1;13(1):29-32. doi: 10.1089/aid.1997.13.29. AIDS Res Hum Retroviruses. 1997. PMID: 8989424 Clinical Trial.

6

Drug companies have a duty to continue treatment.

Emery S, Cooper DA. Emery S, et al. BMJ. 1997 Mar 22;314(7084):889. doi: 10.1136/bmj.314.7084.889. BMJ. 1997. PMID: 9093106 Free PMC article. No abstract available.

7

A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.

Carr A, Chuah J, Hudson J, French M, Hoy J, Law M, Sayer D, Emery S, Cooper DA. Carr A, et al. Among authors: emery s. AIDS. 2000 Jun 16;14(9):1171-80. doi: 10.1097/00002030-200006160-00014. AIDS. 2000. PMID: 10894281 Clinical Trial.

8

Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease.

Emery S, Capra WB, Cooper DA, Mitsuyasu RT, Kovacs JA, Vig P, Smolskis M, Saravolatz LD, Lane HC, Fyfe GA, Curtin PT. Emery S, et al. J Infect Dis. 2000 Aug;182(2):428-34. doi: 10.1086/315736. Epub 2000 Jul 28. J Infect Dis. 2000. PMID: 10915072 Clinical Trial.

9

Lipodystrophy following antiretroviral therapy of primary HIV infection.

Miller J, Carr A, Smith D, Emery S, Law MG, Grey P, Cooper DA. Miller J, et al. Among authors: emery s. AIDS. 2000 Oct 20;14(15):2406-7. doi: 10.1097/00002030-200010200-00025. AIDS. 2000. PMID: 11089632 No abstract available.

10

HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.

Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, Smith D, Kaldor J, Cooper DA. Miller J, et al. Among authors: emery s. HIV Med. 2003 Jul;4(3):293-301. doi: 10.1046/j.1468-1293.2003.00159.x. HIV Med. 2003. PMID: 12859330 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,035 results

Search Page

Filters